Diplomatic Trade Acquires Major Stake in Turkish Pharmaceutical Company, Plans $300M Biopharma Expansion

A significant cross-border pharmaceutical investment is set to transform healthcare manufacturing in the Middle East and North Africa (MENA) region, as Diplomatic Trade Ltd and Diplomatic Trade Capital Group acquire a controlling stake in a prominent Turkish pharmaceutical conglomerate.

The strategic acquisition involves a 49% equity position in the Turkish pharmaceutical group, positioning the companies to develop a next-generation bio-manufacturing facility in the United Arab Emirates by the third quarter of 2025. This facility will specialize in biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals targeting growing healthcare demands across Gulf states and North Africa.

The proposed manufacturing site will incorporate advanced technologies, including AI-driven quality control, biocompatible packaging, and modular production suites compliant with European Union Good Manufacturing Practice (EU-GMP) standards. This approach signals a significant leap in pharmaceutical innovation and infrastructure development in the region.

With an ambitious roadmap, the newly formed group is targeting an initial public offering (IPO) on a leading UAE stock exchange in the fourth quarter of 2025. Preliminary valuations suggest the company could be worth approximately $300 million, driven by strong projected earnings, extensive distribution rights across the Gulf Cooperation Council (GCC) region, and a robust pipeline of proprietary therapeutic treatments.

The transaction has been financially supported by Morgan Brookshire LLC, a U.S.-based private family office, underscoring the transatlantic commitment to developing critical pharmaceutical infrastructure in the Gulf region. This investment also represents a strategic alignment with broader economic collaboration between the United States and GCC countries in the life sciences sector.

By establishing this venture, Diplomatic Trade Ltd is positioning itself as a key player in regional life sciences consolidation. The company aims to bridge institutional capital with high-growth frontier markets, leveraging deep regulatory insights and geopolitical positioning.

The pharmaceutical group's extensive experience in manufacturing, warehousing, and distributing advanced generic drugs and biosimilars across Eastern Europe, MENA, and Central Asia provides a strong foundation for this ambitious expansion. The partnership represents a significant step toward enhancing pharmaceutical sovereignty and improving healthcare access in the region.